09th March 2022 | Pharma Updates
The combination of Covishield and Covaxin improves immunity: ICMR
A study conducted by ICMR discovered that combining the two primary Covid19 vaccines — Covishield and Covaxin — produced a greater immune response than a single dosage schedule.
Zydus' US affiliate purchases a specialty drug asset in the United States
Zydus Lifesciences announced that its US subsidiary Sentynl Therapeutics has agreed to acquire Nasdaq-listed BridgeBio Pharma’s specialty asset Nulibry (fosdenopterin), which is used in the treatment of a rare genetic condition that affects children.
Saluda Medical's Evoke Spinal Cord Stimulation System has been approved by the FDA to treat chronic intractable pain
Transformative closed-loop technology analyses the spinal cord’s response to stimulation and optimal treatment, announced that the Evoke Spinal Cord Stimulation System has gained full FDA approval.
Inspirata Receives First FDA Clearance for Scanner Agnostic Digital Pathology Software
Inspirata, a provider of digital pathology and cancer informatics, announced that its Dynamyx digital pathology software has been cleared by the US Food and Drug Administration (FDA).
Revance resubmits to the FDA a Biologics License Application for DaxibotulinumtoxinA
Neural Sleeve is the first algorithmpowered bionic garment designed to help those with mobility issues due to Multiple Sclerosis, Stroke, Cerebral Palsy, and other conditions regain functional movement in everyday activities. It will be available later this year.
Moderna signs agreement with Kenya to build Africa's first mRNA facility
Moderna announced the signing of a memorandum of understanding with Kenya’s government for the establishment of the drugmaker’s first mRNA vaccine manufacturing plant in Africa.
According to CDC, Omicron sub-variant BA.2 accounts for 11.6% of COVID variants in the US
The BA.2 sub-variant of Omicron was predicted to account for 11.6% of coronavirus variations circulating in the United States as of March 5, according to the Centers for Disease Control and Prevention (CDC).
Amyrt Receives FDA Complete Response Letter for Oleogel-S10 Treatment of Epidermolysis Bullosa
Amryt, a worldwide, commercial-stage biopharmaceutical company for rare diseases, announced that it has received CRL from the FDA regarding its new drug application (NDA) for Oleogel-S10.
FDA has declared that gene-edited cattle are safe to eat
USFDA approved the sale of beef from gene-edited cattle. After salmon and pigs, cattle created by Recombinetics are the third genetically modified species allowed for human consumption in the United States.
In a mouse study, scientists discover a viable weight loss medicine
A novel appetite suppressor has been discovered, according to experts at Northwest A&F University in Shaanxi, China. It is camptothecin, a medication that was originally considered for use as an anticancer agent.